Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAROUSEL: CD19CAR T-cells for Relapsed/Refractory Primary CNS Lymphoma
NCT04443829Phase 1Active, not recruiting
- Sponsor
- University College London
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in primary central nervous system lymphoma (PCNSL), sponsored by University College London. Primary endpoints: Incidence of grade 3-5 toxicity causally related to the ATIMP at 28 days and Feasibility of manufacturing CD19CAR T-cells at 28 days. Started Mar 2021; status: active, not recruiting.
02
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04443829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443829.